Key terms
About KRTX
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KRTX news
Mar 18
9:23am ET
Karuna Therapeutics Undergoes Extensive Corporate Transformation
Mar 18
9:07am ET
Bristol Myers completes acquisition of Karuna Therapeutics
Mar 14
8:30am ET
Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)
Mar 11
6:30am ET
Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)
Mar 05
1:31am ET
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
Feb 28
12:20am ET
Analysts Offer Insights on Healthcare Companies: Raffles Medical Group (OtherRAFLF), Agilent (A) and Karuna Therapeutics (KRTX)
Feb 26
9:30pm ET
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
Feb 23
12:17am ET
JMP Securities Reaffirms Their Hold Rating on Karuna Therapeutics (KRTX)
Feb 22
6:34am ET
Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65)
Feb 08
7:33am ET
Neurocrine price target raised to $106 from $100 at Piper Sandler
Jan 26
4:50am ET
Karuna Therapeutics downgraded to Neutral from Buy at Mizuho
Jan 26
4:50am ET
Analysts Conflicted on These Healthcare Names: Karuna Therapeutics (KRTX) and Health Catalyst (HCAT)
Jan 03
10:47am ET
The biopharmaceuticals stocks to own in 2024, according to BofA
Jan 03
6:12am ET
Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
Jan 02
6:26am ET
Karuna Therapeutics price target raised to $330 from $197 at UBS
Dec 29
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)
Dec 28
4:51am ET
Karuna Therapeutics downgraded to Neutral from Overweight at JPMorgan
Dec 27
7:59am ET
RayzeBio deal another ‘incremental positive’ for Bristol, says Morgan Stanley
Dec 27
7:45am ET
Karuna Therapeutics (KRTX) was downgraded to a Hold Rating at Maxim Group
Dec 26
10:04am ET
Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
Dec 26
8:38am ET
M & A News: Bristol-Myers (NYSE:BMY) Snaps Up RayzeBio (NASDAQ:RYZB) for $4.1B
Dec 26
6:17am ET
Karuna deal favorable for Axsome Therapeutics, says H.C. Wainwright
Dec 26
6:16am ET
Karuna Therapeutics Acquisition: Hold Rating with Adjusted Price Target Reflecting Near-Term Valuation
Dec 26
6:13am ET
Reviva may be most undervalued in neurology, says H.C. Wainwright
Dec 26
6:06am ET
Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Dec 22
4:14pm ET
Karuna Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
Dec 22
4:12pm ET
Karuna Therapeutics downgraded to Market Perform from Outperform at Leerink
Dec 22
1:10pm ET
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Karuna Therapeutics (KRTX)
Dec 22
12:52pm ET
Karuna Therapeutics downgraded to Hold from Buy at Deutsche Bank
Dec 22
12:48pm ET
Karuna Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Dec 22
12:46pm ET
Karuna Therapeutics downgraded to Hold from Buy at Maxim
No recent news articles are available for KRTX
No recent press releases are available for KRTX
KRTX Financials
Key terms
Ad Feedback
KRTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KRTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range